354P - Survival trends of primary testicular diffuse large B-cell lymphoma: A population-based study
|Date||18 December 2016|
|Event||ESMO Asia 2016 Congress|
|Citation||Annals of Oncology (2016) 27 (suppl_9): ix104-ix111. 10.1093/annonc/mdw586|
M. Mousa, A. Meshref
Primary Testicular lymphoma is considered a rare disease with a limited data on its survival trends and outcomes of treatment. In our study, we aimed at evaluation of 5-year relative survival rates of these patients in a large sample using the Surveillance, Epidemiology, and End Results (SEER) Registry of the United States.
Kaplan-Meir method was used to analyze the 5-year relative survival rates of 1074 primary testicular diffuse large B-Cell lymphoma cases using SEER*Stat Program. Relative survival rates were calculated using Z-test among groups of patients categorized by year of diagnosis, race, age groups and laterality.
We found a statistically significant increase in the relative survival rates in the group of patients diagnosed in and after the year of 2000 which is the year of introduction of rituximab to the treatment protocols (66.8% ± 2.6%) in comparison to patients diagnosed before the year of 2000 (54.1% ± 3.3%, P = 0.005). When the study population was categorized according to age at diagnosis (18-59, 60-69, 70-79 and older than 80 years old) the 5-year relative survival rates were 96.5%, 62.7% 59.9% and 46.1% respectively (P
The introduction of rituximab to the treatment protocols, younger age at the time of diagnosis and unilateral tumors seems to have better relative survival rates in such cases. Such results can be used in reforming the disease surveillance and prognostic counseling programs in a better manner.
Clinical trial indentification
Legal entity responsible for the study
The Surveillance, Epidemiology, and End Results (SEER) Program of the American National Cancer Institute
Suez Canal University
All authors have declared no conflicts of interest.